ADAM17 is a type I transmembrane glycoprotein which belongs to the ADAM (a disintegrin and metalloprotease domain) family. ADAM17 functions as a tumor necrosis factor-alpha converting enzyme (TACE). ADAM17 also causes a number of inflammatory modulators to undergo ectodomain shedding, including TNFR75, IL-1RII, TNFR55, L-selectin, and the amyloid precursor protein among others. ADAM17 plays a prominent role in the activation of the Notch signalling pathway. It also plays a pivotal role in several acquired tumor cell capabilities by mediating the availability of soluble transforming growth factor-alpha, and establishing an autocrine signaling pathway through endogenous EGFR activation. ADAM17 is therefore a prospective therapeutic target in human cancer.
Applications:
Suitable for use in Immunohistochemistry. Other applications not tested.
Recommended Dilution:
Immunohistochemistry (paraffin): 20ug/ml
Optimal dilutions to be determined by the researcher.
Positive Control:
Human skeletal muscle
Storage and Stability:
May be stored at 4 degrees C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile 40-50% glycerol, aliquot and store at -20 degrees C. Aliquots are stable for at least 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Quick Search
Products 
